EP2928470A4 - Dérivés de thiénopyridine pour le traitement et la prévention d'infections par le virus de la dengue - Google Patents

Dérivés de thiénopyridine pour le traitement et la prévention d'infections par le virus de la dengue

Info

Publication number
EP2928470A4
EP2928470A4 EP13859644.0A EP13859644A EP2928470A4 EP 2928470 A4 EP2928470 A4 EP 2928470A4 EP 13859644 A EP13859644 A EP 13859644A EP 2928470 A4 EP2928470 A4 EP 2928470A4
Authority
EP
European Patent Office
Prior art keywords
prevention
treatment
dengue virus
virus infections
thienopyridine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP13859644.0A
Other languages
German (de)
English (en)
Other versions
EP2928470A1 (fr
Inventor
Dongcheng Dai
James R Burgeson
Shanthakumar R Tyavanagimatt
Chelsea M Byrd
Dennis E Hruby
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siga Technologies Inc
Original Assignee
Siga Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/708,224 external-priority patent/US20130129677A1/en
Application filed by Siga Technologies Inc filed Critical Siga Technologies Inc
Publication of EP2928470A1 publication Critical patent/EP2928470A1/fr
Publication of EP2928470A4 publication Critical patent/EP2928470A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP13859644.0A 2012-12-07 2013-12-06 Dérivés de thiénopyridine pour le traitement et la prévention d'infections par le virus de la dengue Withdrawn EP2928470A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/708,224 US20130129677A1 (en) 2009-02-27 2012-12-07 Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
PCT/US2013/073449 WO2014089378A1 (fr) 2012-12-07 2013-12-06 Dérivés de thiénopyridine pour le traitement et la prévention d'infections par le virus de la dengue

Publications (2)

Publication Number Publication Date
EP2928470A1 EP2928470A1 (fr) 2015-10-14
EP2928470A4 true EP2928470A4 (fr) 2015-12-16

Family

ID=50884015

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13859644.0A Withdrawn EP2928470A4 (fr) 2012-12-07 2013-12-06 Dérivés de thiénopyridine pour le traitement et la prévention d'infections par le virus de la dengue

Country Status (4)

Country Link
EP (1) EP2928470A4 (fr)
JP (1) JP2016501883A (fr)
CA (1) CA2893318A1 (fr)
WO (1) WO2014089378A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105418635A (zh) * 2015-12-25 2016-03-23 上海应用技术学院 一种噻吩并吡啶类医药中间体的合成方法
CN105832734B (zh) * 2016-03-31 2018-05-04 南通江海港建设工程有限公司 一种化合物在增加血小板浓度药物中的用途
CN105769866B (zh) * 2016-03-31 2018-05-04 南通江海港建设工程有限公司 一种化合物在增加血小板浓度药物中的用途
US10689394B2 (en) 2016-06-14 2020-06-23 The University Of Tokyo Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof
JP2021501582A (ja) 2017-11-03 2021-01-21 ウニヴェルシテ ド モントリオールＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｍｏｎｔｒｅａｌ 化合物及び幹細胞及び／又は前駆細胞の増殖におけるその使用
KR20210057704A (ko) * 2018-06-06 2021-05-21 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) Epac 억제제로서의 티에노[2,3-b]피리딘 유도체 및 이들의 약학적 용도
KR20220066067A (ko) * 2019-08-21 2022-05-23 더 스크립스 리서치 인스티튜트 인터페론 유전자의 자극인자 sting의 비시클릭 효능제
CN111072463A (zh) * 2019-12-03 2020-04-28 辽宁凯莱英医药化学有限公司 一种4-乙氧基-1,1,1-三氟-3-丁烯-2-酮的连续化合成方法
WO2021108999A1 (fr) * 2019-12-03 2021-06-10 辽宁凯莱英医药化学有限公司 Procédé de synthèse en continu de 4-éthoxy-1,1,1-trifluoro-3-butèn-2-one
WO2021250231A1 (fr) * 2020-06-12 2021-12-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Dérivés de thiénopyridine destinés à être utilisés dans le traitement d'une infection à coronavirus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151544A1 (en) * 2000-04-27 2002-10-17 Masahiko Hayakawa Fused heteroaryl derivatives
WO2006068618A1 (fr) * 2004-12-23 2006-06-29 Astrazeneca Ab Nouveaux composés
JP2006298909A (ja) * 2005-03-25 2006-11-02 Tanabe Seiyaku Co Ltd 医薬組成物
WO2007136776A2 (fr) * 2006-05-17 2007-11-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ligands de pyrimidine de faible poids moléculaire destinés à moduler des récepteurs hormonaux

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0785193A4 (fr) * 1994-09-22 2000-04-19 Rational Drug Design Lab Derive d'arylthiadiazole et agent antiviral le contenant
GB9717576D0 (en) * 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
US7202363B2 (en) * 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
AR048669A1 (es) * 2004-03-03 2006-05-17 Syngenta Ltd Derivados biciclicos de bisamida
US20130129677A1 (en) * 2009-02-27 2013-05-23 Siga Technologies, Inc. Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
EP2400845B1 (fr) * 2009-02-27 2017-02-22 Siga Technologies, Inc. Dérivés de la thiénopyridine pour le traitement et la prévention d'infections par le virus de la dengue
WO2011006158A2 (fr) * 2009-07-10 2011-01-13 University Of Maryland, Baltimore Ciblage de la biosynthèse de la nad dans des bactéries pathogènes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151544A1 (en) * 2000-04-27 2002-10-17 Masahiko Hayakawa Fused heteroaryl derivatives
WO2006068618A1 (fr) * 2004-12-23 2006-06-29 Astrazeneca Ab Nouveaux composés
JP2006298909A (ja) * 2005-03-25 2006-11-02 Tanabe Seiyaku Co Ltd 医薬組成物
WO2007136776A2 (fr) * 2006-05-17 2007-11-29 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Ligands de pyrimidine de faible poids moléculaire destinés à moduler des récepteurs hormonaux

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2014089378A1 *

Also Published As

Publication number Publication date
CA2893318A1 (fr) 2014-06-12
JP2016501883A (ja) 2016-01-21
EP2928470A1 (fr) 2015-10-14
WO2014089378A1 (fr) 2014-06-12

Similar Documents

Publication Publication Date Title
ZA201500921B (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases
IL244431A0 (en) Pharmacy methods and preparations for the treatment of hepatitis b virus infection
HK1210463A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
ZA201405820B (en) Piperidino-pyrimidine derivatives for the treatment of viral infections
HK1203944A1 (zh) 用於治療和預防乙型肝炎病毒感染的 -甲基-二氫嘧啶類
HK1222398A1 (zh) 治療伯克霍爾德氏菌感染症的組合物及方法
EP2400845A4 (fr) Dérivés de thiénopyridine pour le traitement et la prévention d'infections par le virus de la dengue
IL236221A (en) History of theophyridone and pharmacological preparations containing them for the treatment of diseases
EP2928470A4 (fr) Dérivés de thiénopyridine pour le traitement et la prévention d'infections par le virus de la dengue
HK1210022A1 (en) Methods for the treatment of hepatitis b and hepatitis d infections
PL2931289T3 (pl) Chityna lub jej pochodne do zapobiegania i/lub leczenia parazytoz
HK1211221A1 (en) Formulations for the treatment and prevention of obesity
PL3082845T3 (pl) Sposoby i kompozycje do leczenia neuropatii obwodowych
HK1201181A1 (en) Novel cyclosporin derivatives for the treatment and prevention of viral infections
HK1206594A1 (en) Materials and methods for prevention and treatment of viral infections
HK1205680A1 (en) Agent for the treatment of hepatitis c virus
AP2015008726A0 (en) Low-glycerin-formulations for hiv treatment and prevention
ZA201407866B (en) Composition for the prevention and treatment of viral infections caused by retroviruses
AU2012905097A0 (en) Agents and methods for inhibiting virus infection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150701

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BYRD, CHELSEA, M.

Inventor name: BURGESON, JAMES, R.

Inventor name: HRUBY, DENNIS, E.

Inventor name: DAI, DONGCHENG

Inventor name: TYAVANAGIMATT, SHANTHAKUMAR, R.

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20151113

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4365 20060101AFI20151109BHEP

Ipc: A61K 31/4375 20060101ALI20151109BHEP

Ipc: C07D 495/14 20060101ALI20151109BHEP

Ipc: C07D 495/06 20060101ALI20151109BHEP

Ipc: C07D 495/22 20060101ALI20151109BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TYAVANAGIMATT, SHANTHAKUMAR, R.

Inventor name: BURGESON, JAMES, R.

Inventor name: HRUBY, DENNIS, E.

Inventor name: BYRD, CHELSEA, M.

Inventor name: DAI, DONGCHENG

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20170713

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20171124